Pancreatic Cancer Genetics in Ashkenazi Jewish Patients
This observational study aims to understand the frequency of three specific genetic changes (mutations) in the BRCA1 and BRCA2 genes among Ashkenazi Jewish patients with pancreatic cancer. These mutations are 185delAG and 5382insC for BRCA1, and 6174delT for BRCA2. The study will look at about 100 patients who have been diagnosed with pancreatic cancer and are of Ashkenazi Jewish descent. You must also be part of the Columbia Pancreatic Cancer Prevention Program Registry and Tissue Bank. The main goal is to see how often these BRCA1/2 mutations appear, which could help in early screening and treatment for family members at risk.
- Study design
- This is an observational study involving about 100 participants. It is not testing a new treatment but rather observing genetic information.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcome, the frequency of BRCA1/2 mutations, will be measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pancreatic Cancer Genetics
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Fay Kastrinos, MD · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Frequency of Three BRCA1/2 Mutations in Ashkenazi Jewish Patients1 year
The primary aim of this study is to determine the combined frequency of BRCA1 (185delAG, 5382insC) and BRCA2(6174delT) mutations in Ashkenazi Jewish pancreatic cancer patients.